ArticleFrontiers in pharmacology2026
A machine learning model integrating gut microbiota biomarkers for predicting neurological recovery after cerebral hypoxia-ischemia: a single-center study augmented with public data.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the predictive value of gut microbiota biomarkers for neurological recovery after cerebral hypoxia-ischemia and to develop a clinically oriented, validated machine learning (ML) for early outcome prediction. Methods: In this single-center cohort study, 772 patients (2022-2024) were stratified according to 1-year neurological outcomes into favorable (n = 538) and poor recovery (n = 234) groups, gut microbiota composition, microbial metabolites, systemic inflammatory and oxidative stress markers, and selected gene expression profiles were assessed using blood and fecal samples. Microbial profiling was assessed via 16S rRNA sequencing and whole-genome sequencing. LASSO regression, random forest (RF), and neural networks models were constructed and evaluated using internal validation strategies and augmented with publicly available datasets. Results: Patients with favorable neurological recovery exhibited significantly higher levels of short-chain fatty acids, increased superoxide dismutase activity, and upregulated neuroprotective gene expression, along with reduced pro-inflammatory cytokines and harmful metabolites (all Conclusion: Gut microbiota-associated biomarkers, when combined with systemic inflammatory indicators such as IL-6, enable robust early prediction of neurological recovery following cerebral hypoxia-ischemia. ML-based integration of multi-modal biomarkers may facilitate clinically applicable prognostic assessment, while also providing a foundation for future investigations into microbiota-targeted interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.